Cargando…
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation
Combined radiochemotherapy is the currently used therapy for locally advanced pancreatic ductal adenocarcinoma (PDAC), but normal tissue toxicity limits its application. Here we test the hypothesis that inhibition of ATR (ATM-Rad3-related) could increase the sensitivity of the cancer cells to radiat...
Autores principales: | Fokas, E, Prevo, R, Pollard, J R, Reaper, P M, Charlton, P A, Cornelissen, B, Vallis, K A, Hammond, E M, Olcina, M M, Gillies McKenna, W, Muschel, R J, Brunner, T B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542617/ https://www.ncbi.nlm.nih.gov/pubmed/23222511 http://dx.doi.org/10.1038/cddis.2012.181 |
Ejemplares similares
-
Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
por: Pires, I M, et al.
Publicado: (2012) -
VE-822 mediated inhibition of ATR signaling sensitizes chondrosarcoma to cisplatin via reversion of the DNA damage response
por: Liang, Xiao, et al.
Publicado: (2019) -
NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
por: Fokas, Emmanouil, et al.
Publicado: (2012) -
Berzosertib (VE-822) inhibits gastric cancer cell proliferation via base excision repair system
por: Ni, Fubiao, et al.
Publicado: (2019) -
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
por: Hall, Amy B., et al.
Publicado: (2014)